MCKMcKesson Corporation

$938.60+36% 1Y

$938.60

$695.0052 weeks$994.59

Is the price fair?

Fair

Neither cheap nor expensive: nothing decisive, though modest expectations priced in.

1 good, 1 neutral, 1 without data

What the price assumes~+1% a yearderived · Jun 30, 2026

Priced for ~1% a year FCF growth. The price demands less than its three-year revenue growth of 13% a year, expectations look modest.

Vs its own P/E rangemid-range for this companyderived

In its normal range: P/E 25.2 vs a 23.6 median over 31 quarters (+7% vs median).

Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.

McKesson Corporation trades at 25.2× earnings against 26.2× for the median Healthcare name, cheaper than its own group.

25.2

Trailing P/E · Healthcare median 26.2 · cheaper than the typical name in its group

Price / sales: 0.22
Price / sales · as of 2026-Q2
Free cash flow yield: 7.3%
Free cash flow yield · Healthcare median 4.8%
Growth the price implies: +0.62%
Growth the price implies · The price pays for +0.62% free cash flow growth a year for a decade; the business has delivered +11% a year over the last three.

Details›

EV / EBIToperating margin 1.6%: the multiple describes the denominator: not meaningful
EV / salesas of 2026-Q2: 0.23
Healthcare median P/E509 names: 26.2
Free cash flow, trailing twelve months: $6.42B
Market capitalisation: $87.9B
3-year revenue growth: +13%
3-year free cash flow growth: +11%

What the market has paid for these earnings: 31 quarters of its own multiple × $37.31 of trailing earnings per share
Method	Per share
Its own P/E history, lower quartile	$609.09
Its own P/E history, median	$880.79
Its own P/E history, upper quartile	$969.54
52-week range	$695.00 – $994.59
Today	$938.60

Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.

Ranks #2 of 446 by RyuScore